CMBGinactive

CELLULAR BIOMEDICINE GROUP, INC.

Healthcare·Oncology·Commercial
OncologyGene TherapyNeurologyImmunologyDermatologyNephrologyMusculoskeletal

CELLULAR BIOMEDICINE GROUP, INC. (CMBG): 18 pipeline candidates · ~6 mo cash runway · 13 clinical trials. Updated within the last hour.

6.7/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.7

6.0 months

Financial Health5.0

D/E 4.37 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

18 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CELLULAR BIOMEDICINE GROUP, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$26.0M

Quarterly Burn

$13.4M

Runway

6.0 mo

Revenue

$32K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Dec 2026
Today~7 mo out
Catalyst within runway

Pipeline (18 candidates)

Showing 10 of 18 candidates. Sign up for full pipeline.

13 clinical trials·CEO: On November

Frequently asked questions

How many drug candidates are in CELLULAR BIOMEDICINE GROUP, INC.'s pipeline?

CELLULAR BIOMEDICINE GROUP, INC. (CMBG) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CELLULAR BIOMEDICINE GROUP, INC.'s lead drug candidate?

CELLULAR BIOMEDICINE GROUP, INC.'s most advanced tracked candidate is afp-tcr-t (Phase 1) for hepatocellular carcinoma (HCC).

What is CELLULAR BIOMEDICINE GROUP, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CELLULAR BIOMEDICINE GROUP, INC. has approximately 6.0 months of cash runway.

Who is the CEO of CELLULAR BIOMEDICINE GROUP, INC.?

On November is the chief executive officer of CELLULAR BIOMEDICINE GROUP, INC. (CMBG).

Get the full picture on CELLULAR BIOMEDICINE GROUP, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.